Amarin Corp Plc (AMRN)

[sts66]

HCQ has shown no benefit in real RCT's, and the FDA withdrew it's EUA a few days ago. From Bill's reply to you I found this link on the UK's RECOVERY trial, which halted it's HCQ arm, probably part of the FDA's decision:

https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19

‘A total of 1542 patients were randomised to hydroxychloroquine and compared with 3132 patients randomised to usual care alone. There was no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes.

To the stats guys here, if R-IT had any result with [95% confidence interval 0.98-1.26]; p=0.10), how would it have been viewed? I think I know the answer - if CI crosses 1 or p > 0.05 you've proven nothing, the result could be due to chance - but in this case they ignored how stats are properly interpreted - why?